Leadership & Pay ·
AgomAb Therapeutics NV announced the proposed appointments of Marino Garcia and Dr. Naimish Patel as non-executive…
AGMBAgomAb Therapeutics NV
AgomAb Therapeutics NV announced the proposed appointments of Marino Garcia and Dr. Naimish Patel as non-executive directors, with shareholder approval scheduled for a Special General Meeting on September 11, 2026. The company also plans to hold an Extraordinary General Shareholders’ Meeting to consolidate and split outstanding pre-IPO subscription rights at a ratio of 21.6450216450216-to-1, aligning them with the share structure established during its February 2026 IPO. This adjustment simplifies management by ensuring each subscription right entitles holders to subscribe for one new ordinary share while proportionally adjusting exercise prices. AgomAb Therapeutics NV is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for fibro-inflammatory diseases.